Upregulation of OX40-OX40 ligand system on T lymphocytes in patients with acute coronary syndromes

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 5, 2009, Pages 451-455

  Yan, Jinchuan ^a   Chen, Guanghua ^a   Gong, Jie ^a   Wang, Cuiping ^a   Du, Rongzeng ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Acute coronary syndromes; Atherosclerosis; OX40; OX40 ligand; SOX40L

Indexed keywords

C REACTIVE PROTEIN; CD134 ANTIGEN; OX40 LIGAND;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OX40 LIGAND; PREDICTIVE VALUE OF TESTS; UP-REGULATION;

EID: 74349123377     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181be7578     Document Type: Article

References (19)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
2. Hansson GK, Libby P. The immune response in atherosclerosis: a doubleedged sword. Nat Rev Immunol. 2006;6:508-519.
3. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581.
4. Mendel I, Shevach EM. Activated T cells express the OX40 ligand: requirments for induction and costimulatory function. Immunology. 2006; 117:196-204.
5. Liu DM, Yan JC, Wang CP, et al. The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta. 2008;397:22-26.
6. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-428.
7. Croft M. Co-stimulatory members of the TNFR family:keys to effective T-cell immunity? Nat Rev Immunol. 2003:3:609-620.
8. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting if the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004; 4:420-431.
9. Wang X, Ria M, Kelmenson PM. Positional idendification of TNFSF4, encodingOX40 ligand, as a gene that inflences atherosclerosis susceptibility. Nat Genet. 2005;4:365-372.
10. Van Wanrooij EJ, Van Puijvelde GH, De Vos P, et al. Interruption of the Tnfrsf4/Tnfsf4(OX40/OX40L) pathway attenuates atherogenesis in lowdensity lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:204-210.
11. Ria M, Eriksson P, Boquist S. Human genetic evidence that OX40 is implicated in myocardial infarction. Biochem Biophys Res Commun. 2006;339:1001-1006.
12. Brunetti ND, Troccoli R, Correale M, et al. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol. 2006; 109:248-256.
13. Kim H, Yang DH, Park Y, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J. 2006;70:1379-1384.
14. Jahn J, Hellmann I, Maass M, et al. Time-dependent changes of hs-CRP serum concentration in patients with non-ST elevation acute coronary syndrome. Herz. 2004;29:795-801.
15. Yan JC, Zhu J, Gao L, et al. The effect of elevated serum soluble CD40 ligand on the prognotic value in patients with acute coronary syndromes. Clin Chim Acta. 2004:155-159.
16. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
17. Higgins LM, McDonald SA, Whittle N, et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 1999;162:486-493.
18. Nohara C, Akiba H, Nakajima A, et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development of pathogenic T cells. J Immunol. 2001;166: 2108-2115.
19. Hattori T, Usui Y, Okunuki Y. Blockade of the OX40 ligand prolongs corneal allograft survival. Eur J Immunol. 2007;37:3597-3604.